FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890467235> ?p ?o ?g. }

• W2890467235 abstract "6026 Background: The Checkmate 141 randomized trial found that patients with platinum-refractory, recurrent or metastatic (R/M) squamous-cell carcinoma of the head and neck (SCCHN) treated with nivolumab had significantly longer overall survival than those treated with standard, single-agent therapy. However, nivolumab is more expensive than standard treatment. We conducted a cost-effectiveness analysis of nivolumab for the treatment of R/M SCCHN. Methods: We constructed a Markov model to simulate treatment with nivolumab or other single-agent therapy (docetaxel, cetuximab, or methotrexate) for patients with R/M SCCHN. Transition probabilities including disease progression, survival, and toxicity were derived from clinical trial data, while costs (in 2016 US dollars) and health utilities were estimated from the literature. Incremental cost-effectiveness ratios (ICERs), expressed as dollar per quality-adjusted life-year (QALY), were calculated with values less than $100,000/QALY considered cost-effective from a healthcare payer perspective. We conducted one-way and probabilistic sensitivity analyses to examine model uncertainty. Results: Our base-case model found that treatment with nivolumab increased overall cost by $59,000 and improved effectiveness by 0.2443 QALYs compared to single-agent therapy, leading to an ICER of $241,100/QALY. In sensitivity analyses, the model was most sensitive to the cost of nivolumab and assumptions about survival. Nivolumab would become cost-effective if the cost per cycle decreased from $13,432 to $5,716. If we assumed that all patients alive at the end of the Checkmate 141 trial were cured of their disease then nivolumab was still not considered cost-effective (ICER $160,000/QALY). Probabilistic sensitivity analysis also demonstrated relative stability of the cost-effectiveness model and found that treatment with nivolumab was cost-effective 0% of the time at a willingness-to-pay threshold of $100,000/QALY. Conclusions: While nivolumab significantly improves overall survival, at the current cost it would not be considered a cost-effective treatment option for patients with R/M SCCHN." @default.
• W2890467235 created "2018-09-27" @default.
• W2890467235 creator A5025425477 @default.
• W2890467235 creator A5030209734 @default.
• W2890467235 creator A5052232462 @default.
• W2890467235 creator A5057038406 @default.
• W2890467235 creator A5058490970 @default.
• W2890467235 creator A5064099533 @default.
• W2890467235 date "2017-05-20" @default.
• W2890467235 modified "2023-09-27" @default.
• W2890467235 title "Cost-effectiveness of nivolumab for treatment of platinum-resistant recurrent or metastatic squamous cell carcinoma of the head and neck." @default.
• W2890467235 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.6026" @default.
• W2890467235 hasPublicationYear "2017" @default.
• W2890467235 type Work @default.
• W2890467235 sameAs 2890467235 @default.
• W2890467235 citedByCount "1" @default.
• W2890467235 countsByYear W28904672352017 @default.
• W2890467235 crossrefType "journal-article" @default.
• W2890467235 hasAuthorship W2890467235A5025425477 @default.
• W2890467235 hasAuthorship W2890467235A5030209734 @default.
• W2890467235 hasAuthorship W2890467235A5052232462 @default.
• W2890467235 hasAuthorship W2890467235A5057038406 @default.
• W2890467235 hasAuthorship W2890467235A5058490970 @default.
• W2890467235 hasAuthorship W2890467235A5064099533 @default.
• W2890467235 hasConcept C121608353 @default.
• W2890467235 hasConcept C126322002 @default.
• W2890467235 hasConcept C141071460 @default.
• W2890467235 hasConcept C143998085 @default.
• W2890467235 hasConcept C161790260 @default.
• W2890467235 hasConcept C185592680 @default.
• W2890467235 hasConcept C2776530083 @default.
• W2890467235 hasConcept C2776833033 @default.
• W2890467235 hasConcept C2777701055 @default.
• W2890467235 hasConcept C2780030458 @default.
• W2890467235 hasConcept C3018411727 @default.
• W2890467235 hasConcept C3019992690 @default.
• W2890467235 hasConcept C502942594 @default.
• W2890467235 hasConcept C509974204 @default.
• W2890467235 hasConcept C518104683 @default.
• W2890467235 hasConcept C55493867 @default.
• W2890467235 hasConcept C71924100 @default.
• W2890467235 hasConceptScore W2890467235C121608353 @default.
• W2890467235 hasConceptScore W2890467235C126322002 @default.
• W2890467235 hasConceptScore W2890467235C141071460 @default.
• W2890467235 hasConceptScore W2890467235C143998085 @default.
• W2890467235 hasConceptScore W2890467235C161790260 @default.
• W2890467235 hasConceptScore W2890467235C185592680 @default.
• W2890467235 hasConceptScore W2890467235C2776530083 @default.
• W2890467235 hasConceptScore W2890467235C2776833033 @default.
• W2890467235 hasConceptScore W2890467235C2777701055 @default.
• W2890467235 hasConceptScore W2890467235C2780030458 @default.
• W2890467235 hasConceptScore W2890467235C3018411727 @default.
• W2890467235 hasConceptScore W2890467235C3019992690 @default.
• W2890467235 hasConceptScore W2890467235C502942594 @default.
• W2890467235 hasConceptScore W2890467235C509974204 @default.
• W2890467235 hasConceptScore W2890467235C518104683 @default.
• W2890467235 hasConceptScore W2890467235C55493867 @default.
• W2890467235 hasConceptScore W2890467235C71924100 @default.
• W2890467235 hasLocation W28904672351 @default.
• W2890467235 hasOpenAccess W2890467235 @default.
• W2890467235 hasPrimaryLocation W28904672351 @default.
• W2890467235 isParatext "false" @default.
• W2890467235 isRetracted "false" @default.
• W2890467235 magId "2890467235" @default.
• W2890467235 workType "article" @default.